April 12 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® AND SOLTI ACHIEVE PRIMARY ENDPOINT IN AWARE-1 STUDY
* ONCOLYTICS BIOTECH INC - PELAREOREP ALONE AND WITH CHECKPOINT BLOCKADE CONVERTS TUMORS TO PD-L1 POSITIVE CLASSIFICATION
* ONCOLYTICS BIOTECH INC - ONCOLYTICS VALIDATES THAT PELAREOREP SIGNIFICANTLY IMPROVES IMMUNOTHERAPIES
* ONCOLYTICS BIOTECH INC - PELAREOREP AND ATEZOLIZUMAB SYNERGIZE ANTI-CANCER IMMUNE RESPONSE IN HR+/HER2- BREAST CANCER PATIENTS